Floatz logo

Fexofenadine

Prostatic Neoplasms, Castration-Resistant

Aragon Pharmaceuticals, Inc.Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Prostatic Neoplasms, Castration-Resistant cohort.

Asset / SponsorPhaseRating
Atezolizumab
Cancer Research UK
Phase 3BB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4B
Jnj-809
Janssen Research & Development, LLC
Phase 2CCC
tqb3616
West China Hospital
Phase 2CCC
Quemliclustat
Arcus Biosciences, Inc.
Phase 1/2CCC

View all 28 →

Same molecule, other indications

Fexofenadine is also rated in:

Fabry diseaseDormant
BB
Indicative ·
69 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →